Overall survival rates for osteosarcoma have remained essentially unchanged over the past 3 decades despite attempts to improve outcome via dose intensification and modification based on response. This review describes recent findings from contemporary clinical trials, advances in the comprehension of osteosarcoma biology and genomic complexity, and potential opportunities using targeted and immunemediated therapies.
INTRODUCTION
Osteosarcoma is the most common primary bone malignancy of childhood and adolescence, with approximately 400 new cases each year in the United States [1] . The current management of newly diagnosed osteosarcoma includes cycles of neoadjuvant chemotherapy which comprised three to four cytotoxic agents (cisplatin, doxorubicin, methotrexate, and ifosfamide), followed by surgical resection of disease and additional cycles of postoperative therapy. Patients with localized disease have a 65-70% 5-year survival rate [2], whereas those who present with metastatic disease (most commonly in the lung parenchyma and distant skeletal sites) experience poor survival rates of 19-30% [3, 4] . Despite numerous attempts in large clinical trials to augment therapy via dose intensification and addition of chemotherapeutic agents, survival rates for osteosarcoma have stagnated over the past 3 decades.
Current efforts within the Children's Oncology Group (COG) and other independent investigators recognize the limitations of continued investigations of a small number of cytotoxic agents in varied schedule and dose to treat a tumor well known for chemotherapy resistance, and have shifted the focus to identifying potential tumor vulnerabilities via genomic aberrations and enzymatic pathways that can be exploited, using novel therapies supported by robust preclinical testing and animal modeling. The purpose of this article is to review the current state of the field, as well as the opportunities for present and future treatment strategies in osteosarcoma.
Recent international collaborations focused on whether survival outcomes could be changed through the modification of adjuvant therapy, with the randomized question for each group based on the histologic response of the resected primary tumor, a well-established prognostic factor. To accrue a large enough patient cohort to complete an appropriately powered study, COG, the Cooperative Osteosarcoma Study Group, the European Osteosarcoma Intergroup, and the Scandinavian Sarcoma Group developed the European and American Osteosarcoma Study Group (EURAMOS-1) clinical trial [5 && ]. The two primary objectives were to determine whether the addition of ifosfamide and etoposide to postoperative chemotherapy would improve outcomes for patients who demonstrated a poor response to standard neoadjuvant chemotherapy (defined as 90% necrosis of the resected primary tumor), and whether the addition of a 2-year maintenance treatment with pegylated interferon alfa-2b (INF-a-2b) after completion of standard treatment would improve outcomes for good responders. The trial required immense collaborative efforts to navigate regulatory and funding barriers, but proved successful in accruing 2260 patients over a 6-year period [5 && ].
Results for each of the primary objectives on EURAMOS-1 have now been reported. For good responders, no significant difference was observed between patients who were treated only with standard cisplatin, doxorubicin and methotrexate (MAP) therapy and those who were randomized to receive INF-a-2b. The analysis was confounded by refusal of a large proportion of randomized patients to start INF-a-2b; of those who received treatment, 39% stopped early, mostly because of toxicity or disease progression [6 && ]. The results of the poor responder cohort were equally disappointing; no difference in 3-year event-free survival (EFS) was observed between the two randomized arms. Those who received ifosfamide and etoposide experienced a significantly greater likelihood of grade 4 nonhematologic toxicities, and were unable to receive the full cumulative doses of chemotherapy. A higher rate of secondary malignant neoplasms was observed, although the difference in the arms was not statistically significant [7 && ].
PROGNOSTIC MARKERS
The results of the EURAMOS-1 trial provide additional evidence that diminishes the value of histologic response as a prognostic marker, with no established ability to impact survival through adjustments of postoperative treatment. As previous literature also demonstrates the inability to augment survival curves through dose intensification and increased rate of histologic response, clinical trials should no longer incorporate histologic response as a reference point for the randomization of postoperative therapy. An increased focus on osteosarcoma biology, pathway analysis, and genetics has provided new potential biologic markers of disease. These include single nucleotide polymorphism (SNP) variants in the nuclear factor I/B (NFIB) gene that affect osteosarcoma cell migration and proliferation, and are associated with metastasis in certain lineages [8] . Several microRNAs have been suggested to impact prognosis; miR-214 is upregulated in osteosarcoma tissues and independently prognostic for progression-free survival (PFS) and overall survival. A locus at 14q32 associated with miR-382, miR-134, and miR-544 has demonstrated an inverse correlation between aggressive tumor behavior and residual expression of micro-RNAs [9,10]. DNA methylation analysis may reveal patterns with prognostic significance [11] . Further evaluation and prospective validation of these markers in future studies will establish their role in the prognostication of tumor response and survival outcomes.
KEY POINTS
Recent collaborative efforts to study osteosarcoma in a randomized fashion failed to demonstrate improvement in outcomes by augmenting postoperative therapy based on histologic response to preoperative chemotherapy.
A new paradigm for osteosarcoma includes rigorous preclinical drug development, understanding of mechanism of action and animal models, paired with a clinical trial model focused exclusively on osteosarcoma with both response and survival end points.
Osteosarcoma harbors striking genetic complexity and interpatient heterogeneity; nearly all osteosarcomas have aberrations of the TP53 pathway.
Several biologic targeted therapies have been identified from recent comprehensive analyses and are being developed for phase II trials to determine efficacy.
Based on the high mutational load, osteosarcoma may be an attractive target for immunotherapy using anti-CTLA-4 and anti-PD-1/PD-L1 therapies.
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A NEW PARADIGM FOR PRECLINICAL DEVELOPMENT AND CLINICAL INVESTIGATION
The EURAMOS-1 trial results provided further proof that improvement of survival outcomes for osteosarcoma would not be achieved through continued adjustments of dose and schedule of the same cytotoxic agents in use for the past 30 years. Concurrently, attempts to develop and conduct large scale clinical trials with novel therapeutic agents have been complicated by three factors: rarity of diagnosis, failure to understand the mechanisms of osteosarcoma biology leading to resistance to most chemotherapeutic agents, and the lack of radiographic regression of bulky lesions with treatment that hinders the ability to measure response by conventional methods. The result of these three factors is the lack of novel agents with activity in the treatment of patients with osteosarcoma. Collaborative efforts have recently focused on providing rigorous preclinical data for the development of new therapeutics before consideration for clinical trials, including a comprehensive understanding of mechanism of action, validation of markers of both exposure and response, and use of animal models (e.g., murine and canine) to assess efficacy [12 && ]. These studies have been supported by the development of the Childhood Sarcoma Biostatistics and Annotation Office, which links patient data to archived tissue samples and provides biostatistical support to researchers [13]. These investigations have begun to yield several promising agents with therapeutic potential, which will be described subsequently.
The need to retrospectively assess prior failures of novel agents was vital to interrogate the standard approach to interpreting clinical response. A pooled analysis was conducted for seven previous phase II trials conducted by COG and its preceding collaborative groups that included strata for recurrent/ refractory osteosarcoma patients with measurable disease. The 4-month EFS was 12%; radiographic responses were observed in only three of the trials
]. Recognizing the limitations of the traditional use of the radiographic response as a primary end point for phase II studies for osteosarcoma, current and future planned clinical investigations of novel therapeutics are incorporating evaluations of 'controlled stable disease' and will be statistically powered to use this measure as a surrogate for PFS. Furthermore, while osteosarcoma remains a rare diagnosis, the development of serial clinical trials of new therapeutics targeted exclusively toward recurrent and refractory osteosarcoma holds promise for accelerating investigations of drug efficacy. The first phase II trial to be developed under this paradigm included eribulin mesylate, a microtubule inhibitor that demonstrated activity in osteosarcoma cell lines and xenografts in the Pediatric Preclinical Testing Program [15] . Although expected to enroll 1.3 patients per month based on prior phase II studies, the trial rapidly accrued 19 patients in 3.5 months [16 & ]. The brief interval observed from enrollment to analysis demonstrates the potential success of such a clinical trial model to expedite the analysis of novel agents for clinical effectiveness, and the willingness of patients to continue to seek new therapies when available.
GENOMIC COMPLEXITY OF OSTEOSARCOMA
As part of efforts to identify targets for novel therapeutic agents, several groups have taken advantage of increasing access to a variety of methods of genomic analysis to analyze osteosarcoma samples via whole genome and exome sequencing, transcriptome evaluation of gene expression, and epigenetic modifications. These investigations have revealed striking genomic complexity, as well as profound interpatient heterogeneity (see Fig. 1 and Fig. 2 ). This includes distinct chromosomal regions of hypermutation referred to as 'kataegis' and a vast number of structural variations [17 & ]. Although p53 aberrancy has long been associated with osteosarcoma via germline mutations in Li-Fraumeni syndrome, recent comprehensive genomic analyses have revealed that nearly all osteosarcomas have alterations of TP53 or associated pathway genes such as mouse double minute 2; mutations in retinoblastoma 1 (RB1), and associated pathway genes are also frequently present [17 & ,18 & ]. Whole-genome sequencing analysis of 19 osteosarcoma tumors revealed that 55% of patients demonstrated a structural variant inactivating TP53, most commonly as a translocation involving intron 1 [17 & ]. Other common alterations revealed from these studies include mutations of DLG2 and alpha thalassemia/mental retardation X (ATRX) [17 & ] and deletions of CDKN2A/B; alterations of members of the phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathways were also identified in 24% of samples in one cohort [18 & ]. Forward genetic screening using Sleeping Beauty transposon mutagenesis enriched for genes in the PI3K/mTOR, erythroblastosis oncogene B (ErbB), and mitogen-activated protein kinase (MAPK) pathways, as well as previously unknown oncogenes related to osteosarcoma such as Sema4d and Sema6d, genes associated with axon guidance [19 & ]. Other methods including genome-wide association studies have revealed SNPs within a locus at the GRM4 gene associated with susceptibility to osteosarcoma [20] , as well as the aforementioned SNP within NFIB which may increase risk of metastasis [8] .
Although p53 and RB1 are suspected of acting as major oncogenic drivers, the lack of intron 1 rearrangements in other p53-associated tumors suggests preexisting genomic instability in osteosarcoma that predisposes to structural variations; Treatments program, which is actively performing integrated multiplatform analyses of osteosarcoma samples [21] . Generation of sufficient genetic and epigenetic data is hoped to enable correlations between genomic changes, tumor biology, and clinical behavior.
TARGETED THERAPIES
Preclinical studies of osteosarcoma biology, genomic and pathway analyses, and drug screening have now provided several therapeutic opportunities to be evaluated in clinical studies (Table 1) . This includes denosumab, a fully human monoclonal antibody targeting the receptor activator of nuclear factor kB ligand (RANKL). RANK signaling promotes motility and anchorage-independent growth of osteosarcoma cells [22] ; transgenic mouse models with alterations of RANKL have been observed to develop osteosarcoma. Preclinical drug screening has also suggested activity of glembatumumab vedotin, which targets the transmembrane glycoprotein NMB (GPNMB; osteoactivin). In Pediatric Preclinical Testing Program testing, glembatumumab demonstrated maintained complete responses in three of six osteosarcoma xenografts [23] . Further testing demonstrated the expression of GPNMB in 92.5% of 67 human osteosarcoma tissue samples and correlation between GPNMB protein expression and in-vitro cytotoxicity [24] . A third potential target for treatment is the disialoganglioside GD2. Anti-GD2 therapy has improved survival outcomes for patients with high-risk neuroblastoma who have minimal residual disease; based on this success, the chimeric anti-GD2 antibody dinutuximab (ch14.18) was recently approved by the Food and Drug Administration. Nearly all osteosarcomas tumors expressed GD2 by immunohistochemistry in a recent investigation [25 & ]; subsequent analysis showed that in relapsed patients, GD2 expression was universally maintained upon recurrence [26] . Several trials utilizing varied forms of anti-GD2 therapy are currently open (NCT02173093; NCT00743496; NCT02107963; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; CSF-1, colony stimulating factor 1; FGFR, fibroblast growth factor receptor; FKBP12, FK506 binding protein-12; FLT3, FMS-like receptor tyrosine kinase-3; mTORC1, mammalian target of rapamycin complex 1; PD-1, programmed death-1; PDGFR-B, platelet derived growth factor receptor beta; TIE2, tunica interna endothelial cell kinase 2; VEGF, vascular endothelial growth factor. a Clinical trials are listed on www.clinicaltrials.gov. and NCT02502786). Clinical trials are currently in development for the use of denosumab, glembatumumab vedotin, and dinutuximab for the treatment of recurrent and refractory osteosarcoma. As noted above, multiple complementary analyses have implicated PI3K/mTOR as a targetable pathway in osteosarcoma [18 & ,19 & ,27] , and that dual inhibition of PI3K and mTOR may abrogate proliferation and induce apoptosis [27] . Several dual PI3K/ mTOR inhibitors are in clinical development; combinations of novel PI3K inhibitors such as buparlisib [28] with existing mTOR inhibitors such as everolimus and temsirolimus warrant investigation. The tyrosine kinase inhibitor sorafenib inhibits cell growth, angiogenesis, and metastasis through inhibition of vascular endothelial growth factor (VEGF) and MAPK/ERK pathways [29] and has been utilized in recent studies as a single agent or in combination [30, 31] . A combination of sorafenib with everolimus increased antitumor activity in vitro and in vivo via abrogation of upregulation of mTORC2 [32] . A recent clinical trial of combined sorafenib and everolimus yielded a 6-month PFS of 45% [33 & ], generating increasing interest in the development of trials incorporating sorafenib or an alternative tyrosine kinase inhibitor with an mTOR inhibitor.
Other druggable targets requiring further preclinical evaluation include cell cycle checkpoints Wee1 and Chk. Use of a Wee1 inhibitor (AZD1775) increases osteosarcoma sensitivity to radiation and enhances cytotoxicity of gemcitabine in cell lines [34, 35] , not only via dysregulation of cell cycle progression and mitotic catastrophe but also through enhancement of replicative stress via reduction of ataxia telangiectasia and Rad3 related (ATR)/Chk1 [36] . Inhibition of ATR is another novel approach to therapy. Osteosarcoma cells employ alternative lengthening of telomeres to overcome replicative senescence [37], a process not infrequently associated with ATRX loss, as seen in a number of osteosarcoma samples [17 & ]. ATR inhibition disrupts alternative lengthening and results in chromosomal fragmentation and apoptosis; osteosarcoma cell lines positive for ALT (U2OS, and SAOS2) treated with the ATR inhibitor VE-821 demonstrated hypersensitivity and increased cell death compared to cell lines with telomerase activity [38] . 
CONCLUSION
Recent efforts to expand opportunities for treatment of osteosarcoma through rigorous preclinical drug development, comprehensive genomic analyses, and the implementation of a histology-exclusive clinical trial model for the investigation of new agents are now beginning to generate a number of therapeutic strategies to be implemented in upcoming studies. We are optimistic that this new paradigm for preclinical and clinical investigation will identify agents with a signal of activity that can be moved forward to new trials in combination with standard chemotherapy, with the goal of improving long-stagnant survival outcomes. 
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